CADENCE PHARMACEUTICALS INC 4
4 · CADENCE PHARMACEUTICALS INC · Filed Dec 3, 2013
Insider Transaction Report
Form 4
Byrd Scott A.
SVP, Chief Commercial Officer
Transactions
- Exercise/Conversion
common stock
2013-12-02$3.51/sh+7,812$27,420→ 9,812 total - Exercise/Conversion
stock option (right to buy)
2013-12-02−7,812→ 70,314 totalExercise: $3.51Exp: 2022-03-14→ common stock (7,812 underlying) - Sale
common stock
2013-12-02$9.16/sh−7,812$71,558→ 2,000 total
Footnotes (3)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2013.
- [F2]25% of the 125,000 shares of common stock originally subject to the option vested on 3/14/2013, and 1/48th of the remaining number of shares of common stock subject to the option vest on the first day of each full month thereafter.
- [F3]Not applicable to this transaction.